June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Optimizing oligotherapeutics for visual loss in Usher syndrome mice
Author Affiliations & Notes
  • Jennifer J Lentz
    Neuroscience Center, LSUHSC, New Orleans, Louisiana, United States
  • Marianne Hathaway
    Neuroscience Center, LSUHSC, New Orleans, Louisiana, United States
  • Katelyn N Robillard
    Neuroscience Center, LSUHSC, New Orleans, Louisiana, United States
  • Abhilash Ponnath
    Neuroscience Center, LSUHSC, New Orleans, Louisiana, United States
  • Mark Fisher
    Neuroscience Center, LSUHSC, New Orleans, Louisiana, United States
  • Frank Rigo
    Ionis Pharmaceuticals, Inc, Carlsbad, California, United States
  • Bhagwat V Alapure
    Neuroscience Center, LSUHSC, New Orleans, Louisiana, United States
  • Footnotes
    Commercial Relationships   Jennifer Lentz, Ionis Pharmaceuticals, Inc (R); Marianne Hathaway, None; Katelyn Robillard, None; Abhilash Ponnath, None; Mark Fisher, None; Frank Rigo, Ionis Pharmaceuticals, Inc (E); Bhagwat Alapure, None
  • Footnotes
    Support  NIH Grant 1R01EY030499-01
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2445. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jennifer J Lentz, Marianne Hathaway, Katelyn N Robillard, Abhilash Ponnath, Mark Fisher, Frank Rigo, Bhagwat V Alapure; Optimizing oligotherapeutics for visual loss in Usher syndrome mice. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2445.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Usher syndrome (Usher) is a syndromic form of inherited retinal dystrophy (IRD) characterized by hearing impairment in combination with retinitis pigmentosa. Although considered rare, it is the most common genetic cause of deaf-blindness. To study mechanisms and develop therapies, we engineered a mouse model to contain the founder mutation (216A) in exon 3 of the USH1C gene responsible for Acadian Usher syndrome (USH1C) and developed a treatment targeting this mutation using antisense oligonucleotides (ASO). USH1C mice treated with 216A-targeted ASOs shows appreciable short-term rescue of visual function. The purpose of this study was to optimize ASO targeting for a longer duration of improved visual function in USH1C mice.

Methods : USH1C mice were treated at post-natal day 21 by intravitreal injection (IVI) with ASOs designed to target different sequences in exon 3 of the Ush1c gene and with various chemical modifications. Ush1c gene expression was measured by RT-PCR and next-generation sequencing. Visual function was measured by electroretinogram (ERG) analysis at 3 and 6 months of age.

Results : USH1C mice treated with ASOs of various sequences containing 2’-O-Methoxyethyl (2’MOE), 2’-O-Methyl (2’ME), morpholino (MO), or vivo-morpholino modifications showed dose dependent improvements in Ush1c expression in the retina 2 weeks post-IVI. Visual function testing showed significantly improved ERGs 14 weeks post-treatment with a single dose of 2’MOE-, MO-modified, or a combination of the two ASOs in USH1C mice compared with untreated or control-treated USH1C mice.

Conclusions : Our results show that ASOs with various chemical modifications and targets in exon 3 of the Ush1c gene delivered locally to the eye can effectively target Ush1c mutations in the retina and improve visual function in USH1C mice. These results suggest the therapeutic potential of ASO intervention to improve gene expression and visual function in Usher syndrome, and IRDs in general. Future studies will include an analysis of aged USH1C mice treated with optimized ASOs to determine the duration of the visual benefits.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×